| Condition |
Trial Name |
Phase |
Sponsor |
| Relapsed Refractory Multiple Myeloma (RRMM) |
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma |
1/2 |
TAKEDA |
| Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma |
A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination with Paclitaxel in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy |
2 |
NATCO |
| High-risk HER2-positive Early-stage Breast Cancer |
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan(T-DXd) Monotherapy or T-DXd followed by THP compared to ddAC-THP in participants with High-risk HER2-positive Early-stage Breast Cancer(DESTINY-Breast11) |
3 |
AstraZeneca |
| Stage I-III Triple-negative Breast Cancer |
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection |
3 |
AstraZeneca |
| ER+HER2- Metastatic Breast Cancer |
A Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm in Combination with Abemaciclib (Enobosarm Combination Group) compared to Estrogen Blocking Agent (Control Treatment Group) for the Second Line Treatment of ER+HER2- Metastatic Breast Cancer in Patients Who Have Shown Previous Disease |
3 |
Veru Inc. |
| Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer |
A Phase 3, Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02) |
|
AstraZeneca |
| B-Cell Malignancies |
A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies |
1/2 |
InnoCare Pharma Inc. |
| Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer |
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of GDC-9545 Combined With PALBOCICLIB Compared With LETROZOLE Combined With PALBOCICLIB In Patients With estrogen receptor-positive, HER2-negative Locally Advanced Or Metastatic Breast Can |
3 |
Genetech_Roche |
| First-line HER2-positive Breast Cancer |
A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in First-line HER2-positive Breast Cancer (DESTINY-Breast09). |
3 |
AstraZeneca |
| Relapsed or Refractory Multiple Myeloma (RRMM) |
A Phase III randomized, open-label trial of SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) in patients with relapsed or Refractory Multiple Myeloma(RRMM). |
3 |
EMN 29 |
| Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
A Phase III, Open-label, Randomized, Multicenter Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-base |
3 |
AstraZeneca |
| HER-positive, HER2-negative locally advanced (recurrent or progressed) or metastatic breast cancer who have had previous treatment with CDK4/6 inhibitors (CDK4/6is) and endocrine therapy (ET). |
A Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with exemestane plus everolimus in patients with ER-positive, HER2-negative locally advanced (recurrent or progressed) or metastatic breast cancer who have had previo |
|
Genetech_Roche |
| Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) |
A Phase III, randomized, open-label, multicenter, global study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC w |
|
AstraZeneca |
| Triple Negative Breast Cancer |
A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy-ASCENT-05 |
3 |
Gilead |
| Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer |
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) |
|
Roche |
| Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) |
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) |
|
Roche-Genetech |
| Stage I-III Triple-negative Breast Cancer |
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy |
|
AstraZeneca |
| Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer |
A phase III, randomized, open-label study evaluating the efficacy and safety of Giredestrant in Combination with phesgo versus phesgo after induction Therapy with Phesgo+taxane in patients with previously untreated her2-positive, estrogen receptor-positive locally-advanced or metastatic breast cance |
3 |
Genetech_Roche |
| Non-Small Cell Lung Cancer (NSCLC) |
A randomized, multicenter, open-label cross-over study to evaluate participant and healthcare professional reported preference for subcutaneous atezolizumab compared with intravenous atezolizumab formulation in participants with non-small cell lung cancer (NSCLC). |
|
Genetech_Roche |
| Second-line and Above Lymphoid Malignancies |
An Open-Label, Phase 1/2 Study Evaluating AVM0703 in Patients with Lymphoid Malignancies (WWRD Study) |
1/2 |
AVM |
| HER2+ Metastatic Colorectal Cancer |
An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer |
3 |
SEAGEN |
| First-line Extensive-stage Small Cell Lung Cancer (ES-SCLC) |
Phase 3 Study of Chemotherapy with MK-7684A or Atezolizumab in First Line ES-SCLC |
3 |
Merck |
